Actively Recruiting
Infrared Photobiomodulation in Humans With Epilepsy
Led by Beth Israel Deaconess Medical Center · Updated on 2026-02-04
13
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise as a possible way to reduce seizures, but it has not been tested in humans for this. The investigators are interested to know if it can reduce seizures, and how comfortable it is to be treated with this therapy.
CONDITIONS
Official Title
Infrared Photobiomodulation in Humans With Epilepsy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Drug resistant epilepsy
- Age 18 or older
- Average seizure rate of at least 2 seizures per month
- Accurate seizure diary with at least 3 months recorded
You will not qualify if you...
- Implanted intracranial neurostimulation device (DBS or RNS)
- Intracranial shunt
- Skin photosensitivity
- Cancer on scalp
- Taking any medication that can cause photosensitivity
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
BIDMC
Boston, Massachusetts, United States, 02215
Actively Recruiting
Research Team
D
Daniel Goldenholz, MD, PhD
CONTACT
D
Daniel Goldenholz, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here